AstraZeneca inks deal with Orca for autoimmune disease drugs

25 February 2015
2019_biotech_test_vial_discovery_big

Anglo-Swedish pharma major AstraZeneca (LSE: AZN) and Orca Pharmaceuticals, a UK based biopharmaceutical company, today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (ROR). Inhibitors of this receptor are believed to have potential against a wide range of autoimmune diseases for which there is currently no safe, effective oral treatment.

ROR plays a key role in the immune system. Specifically, it helps to convert a population of immune cells called CD4+ T cells into T-helper 17 (TH17) cells which, in turn, produce chemicals (cytokines) that drive the immune response. However, excessive activity of TH17 cells and other ROR+ immune cells has been implicated in a wide range of conditions such as inflammatory bowel disease, psoriasis, arthritis and multiple sclerosis.

Deal worth a potential $122.5 million to Orca

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology